Ganquan production base is located in Hanjiang District, Yangzhou, covering an area of 21 acres and a building area of 45,000 m². It has established oral formulation building, sterile formulation building, comprehensive warehouse, quality inspection center, engineering center and supporting sewage treatment facilities. Three additional production buildings are reserved to provide the production capacity of fifteen workshops in the future. Oral solid formulation workshop adopts the first-class domestic pharmaceutical production equipment and establishes 3 modern production lines for tablets, capsules and granules. It has obtained the GMP certificate in May 2017 and has been officially put into operation. The annual production capacity of this workshop is designed to be 1 billion tablets, 500 million capsules and 50 million bags of granules.
Liuzhuang production base is located in Yangzhou Weiyang Economic Development Zone, covering an area of 8 acres, designed as a human urinary protein production base. The company has successfully overcomed the international technical difficulties in large-scale extraction and purification of human urinary proteins by using the patented fresh flow enrichment technology of urinary protein with independent intellectual property rights, and extracted and purified various protein products derived from urine such as crude product/intermediate of : Ulinastatin, Urokinase, Human Urinary Kallidinogenase, Epidermal growth Factor (EGF), highly purified human albumin, and crude β2-microglobulin.
Wuqiao production base is located in Guangling District, Yangzhou. On October 8, 2014, this factory obtained GMP certification (2010 edition) for the first time. At present, the factory has established Sennae Folium extraction workshop and production workshops for Bacillus Cereus Powder and Bacillus Cereus Tablets with relevant supporting facilities and equipment.
Chahe production base is located in Yangzhou Biotechnology Park, covering an area of 11 acres. It focuses on the R&D, production and sales of pharmaceutical intermediates and APIs, and is mainly responsible for providing high-quality APIs for the company. At present, pilot scale-up R&D centers for innovative drugs and multiple API production lines are being constructed.